Huh? This is a non sequitur; we're not assuming they started off with something that far off on a basic metric as Lupenox is on average molecular weight. We both know about the opacity of the ANDA process, and that lack of formal rejection means nothing, so I don't get why you're bringing up competitor's ANDAs.
You honestly think Teva is banging its head on the regulatory wall by continuing on with a candidate that is 15% off of the branded on a basic, major metric?
Regards, RockRat
Market Data 
Markets 
AI
